Evidence map›Paper›PMID 38254847›Full record

ArticleCancers2024

DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.

Mihaela Dragomir, Onda-Tabita Călugăru, Bogdan Popescu, Cerasela Jardan, Dumitru Jardan, Monica Popescu, Silvia Aposteanu, Sorina Bădeliță, Gabriela Nedelcu, Cătălin Șerban and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Mihaela DragomirFaculty of Biology, University of Bucharest, 030018 Bucharest, Romania.ORCID 0000-0001-8529-1107
Onda-Tabita CălugăruFundeni Clinical Institute, 022328 Bucharest, Romania.
Bogdan PopescuHematology Department, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Cerasela JardanFundeni Clinical Institute, 022328 Bucharest, Romania.
Dumitru JardanMolecular Biology Laboratory, Medlife Bucharest, 010093 Bucharest, Romania.
Monica PopescuFundeni Clinical Institute, 022328 Bucharest, Romania.
Silvia AposteanuFundeni Clinical Institute, 022328 Bucharest, Romania.
Sorina BădelițăFundeni Clinical Institute, 022328 Bucharest, Romania.ORCID 0000-0002-1507-2547
Gabriela NedelcuFundeni Clinical Institute, 022328 Bucharest, Romania.
Cătălin ȘerbanFundeni Clinical Institute, 022328 Bucharest, Romania.
Codruța PopaFundeni Clinical Institute, 022328 Bucharest, Romania.
Tatiana Vassu-DimovFaculty of Biology, University of Bucharest, 030018 Bucharest, Romania.
Daniel CoriuFundeni Clinical Institute, 022328 Bucharest, Romania.
Institutul Clinic Fundeni · ROCarol Davila University of Medicine and Pharmacy · ROUniversity of Bucharest · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma is a hematologic neoplasm caused by abnormal proliferation of plasma cells. Sequencing studies suggest that plasma cell disorders are caused by both cytogenetic abnormalities and oncogene mutations. Therefore, it is necessary to detect molecular abnormalities to improve the diagnosis and management of MM. The main purpose of this study is to determine whether NGS, in addition to cytogenetics, can influence risk stratification and management. Additionally, we aim to establish whether mutational analysis of the CD138 cell population is a suitable option for the characterization of MM compared to the bulk population. Following the separation of the plasma cells harvested from 35 patients newly diagnosed with MM, we performed a FISH analysis to detect the most common chromosomal abnormalities. Consecutively, we used NGS to evaluate NRAS, KRAS, BRAF, and TP53 mutations in plasma cell populations and in bone marrow samples. NGS data showed that sequencing CD138 cells provides a more sensitive approach. We identified several variants in BRAF, KRAS, and TP53 that were not previously associated with MM. Considering that the presence of somatic mutations could influence risk stratification and therapeutic approaches of patients with MM, sensitive detection of these mutations at diagnosis is essential for optimal management of MM.

Indexed as

multiple myelomaNGSplasma cells

Identifiers

PMID38254847
PMCPMC10813921
OpenAlexW4390881123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.